NDA 017441 · Allergan
Infed
Iron Dextran · Injection
Priority reviewLast checked: Nov 19, 2026Latest source record: Aug 1, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1974
Apr 29, 1974
Approved uses
1
Original approval plus efficacy supplements
Registered trials
147
40 Phase 3, 12 recruiting
FAERS reports
1,486
956 serious, 124 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
BOXED WARNING WARNING: RISK FOR ANAPHYLACTIC-TYPE REACTIONS Anaphylactic-type reactions, including fatalities, have been reported following the parenteral administration of iron dextran injection. Have resuscitation equipment and personnel trained in the detection and treatment of anaphylactic-type reactions readily available during INFeD administration. Administer a test INFeD dose prior to the first therapeutic dose. If no signs or symptoms of anaphylactic-type reactions follow the test dose, administer the full therapeutic INFeD dose. During all INFeD administrations, observe for signs or symptoms of anaphylactic-type reactions. Fatal reactions have been reported following the test dose of iron dextran injection. Fatal reactions have also occurred in situations where the test dose was tolerated. Use INFeD only in patients in whom clinical and laboratory investigations have...
What it is approved for
From the label in effect Apr 15, 2026.
INFeD is indicated for treatment of adult and pediatric patients of age 4 months and older with documented iron deficiency who have intolerance to oral iron or have had an unsatisfactory response to oral iron. INFeD, an iron replacement product, is indicated for treatment of adult and pediatric patients of age 4 months and older with documented iron deficiency who have intolerance to oral iron or an unsatisfactory response to oral iron. (1)
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 29, 1974 Original approval · Type 5 - New Formulation or New Manufacturer · priority review
1 products under this application
- INFED · IRON DEXTRAN EQ 100MG IRON/2ML (EQ 50MG IRON/ML) · INJECTABLE, INJECTION · Prescription · TE BP
Clinical trials
Interventional ClinicalTrials.gov studies with "Iron Dextran" as an intervention, any sponsor and status, largest first.
- Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRCPivotal-lookingStatus unknown
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT04152486 · 20,426 participants · Start Nov 14, 2019 · Primary completion Jan 31, 2022
Drug: Ad26.ZEBOV, MVA-BN-Filo vaccine · For: Ebola Virus Disease
Sites: Kinshasa, Democratic Republic of the Congo
- Work and Iron Status EvaluationPivotal-lookingCompleted
National Institute on Aging (NIA)NIH
NCT00094042 · 16,000 participants · Start Jan 2002 · Primary completion Jul 2007
Drug: Iron Supplement, 120mg · For: Aging
Sites: Purworejo District, Indonesia
- A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant WomenPivotal-lookingCompleted
Janssen Vaccines & Prevention B.V.Johnson & Johnson (Janssen) (JNJ)
NCT04556526 · 4,031 participants · Start Oct 5, 2020 · Primary completion Mar 2, 2023
Drug: Ad26.ZEBOV; MVA-BN-Filo · For: Healthy
Sites: Cuangugu, Rwanda; Gysenyi, Rwanda; Kigali, Rwanda
- High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Pivotal-lookingCompleted
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01704716 · 3,569 participants · Start Feb 1, 2002 · Primary completion Jan 30, 2025
Drug: Vincristine; Aldesleukin and 9 more · For: Neuroblastoma
Sites: Newcastle, Australia; Sydney, Australia; Vienna, Austria · 122 sites in all
- Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00333840 · 1,106 participants · Start Jun 2000 · Primary completion Mar 2012
Drug: imatinib mesilate; interferon-alpha (INF-a) and 1 more · For: Chronic Myelogenous Leukemia
Sites: Birmingham, Alabama; Montgomery, Alabama; Tucson, Arizona · 163 sites in all
- Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-FiloPivotal-lookingCompleted
Janssen Vaccines & Prevention B.V.Johnson & Johnson (Janssen) (JNJ)
NCT02509494 · 1,023 participants · Start Sep 30, 2015 · Primary completion Jun 28, 2019
Drug: Ad26.ZEBOV; MVA-BN-Filo and 2 more · For: Ebola Virus Disease
Sites: Freetown, Sierra Leone
- Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)Pivotal-lookingCompleted
American Regent, Inc.Industry
NCT00982007 · 997 participants · Start Sep 2009 · Primary completion Mar 2011
Drug: Ferric Carboxymaltose (FCM); Ferrous Sulfate Tablets and 2 more · For: Iron Deficiency Anemia
Sites: Norristown, Pennsylvania
- A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult ParticipantsPivotal-lookingCompleted
Janssen Vaccines & Prevention B.V.Johnson & Johnson (Janssen) (JNJ)
NCT04228783 · 974 participants · Start Feb 18, 2020 · Primary completion Apr 25, 2022
Drug: Ad26.ZEBOV; MVA-BN-Filo and 1 more · For: Ebola
Sites: Mobile, Alabama; Tempe, Arizona; Lexington, Kentucky · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea264
- infusion related reaction167
- nausea126
- flushing115
- anaphylactic reaction112
- back pain111
- chest pain102
- dizziness88
- chest discomfort85
- pruritus81
- off label use80
- hypotension72
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 45 |
| 2005 | 49 |
| 2006 | 48 |
| 2007 | 46 |
| 2008 | 43 |
| 2009 | 39 |
| 2010 | 36 |
| 2011 | 39 |
| 2012 | 60 |
| 2013 | 26 |
| 2014 | 17 |
| 2015 | 34 |
| 2016 | 45 |
| 2017 | 47 |
| 2018 | 68 |
| 2019 | 60 |
| 2020 | 61 |
| 2021 | 99 |
| 2022 | 91 |
| 2023 | 92 |
| 2024 | 143 |
| 2025 | 172 |
| 2026 | 126 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Infed (Iron Dextran Complex) · HCPCS J1750
2024 spending
$11.1M
Beneficiaries
25,311
41,411 claims
Per beneficiary
$440
2024 ASP limit $17.57 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,014,208 |
| 2021 | $7,317,114 |
| 2022 | $7,509,332 |
| 2023 | $5,195,404 |
| 2024 | $11,137,455 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Intravenous versus Oral Iron for Iron-Deficiency Anemia in Pregnancy (IVIDA): A Randomized Controlled Trial.
Lewkowitz AK, Stout MJ, Cooke E, et al. · Am J Perinatol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.
Aksan A, Işk H, Radeke HH, et al. · Aliment Pharmacol Ther 2017 · Systematic Review, Network Meta-Analysis
- Comparative efficacy of intravenous and oral iron supplements for the treatment of iron deficiency in patients with heart failure: A network meta-analysis of randomized controlled trials.
Mei Z, Chen J, Luo S, et al. · Pharmacol Res 2022 · Review, Research Support, Non-U.S. Gov't
- Correction of iron deficiency anaemia using IV CosmoFer in CKD patients with asthma: a prospective study.
Syed A, Bhandari S · QJM 2016 · Clinical Trial
- Economic evaluation of intravenous iron formulations for patients with iron deficiency anemia: a systematic review.
Xing Z, Mu S, Xue Q, et al. · Front Health Serv 2025 · Systematic Review
- Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis.
Shepshelovich D, Rozen-Zvi B, Avni T, et al. · Am J Kidney Dis 2016 · Comparative Study, Meta-Analysis
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.